Patents Assigned to ZATA PHARMACEUTICALS, INC.
  • Patent number: 11566042
    Abstract: Compositions and compounds of nucleoside phosphoramidites and modified oligonucleotides, each comprising one or more charge-neutralizing moieties according to the formula V The nucleoside phosphoramidites permit facile attachment of the neutralizing moieties on the backbones of the modified oligonucleotides. The modified oligonucleotides can be used as therapeutic agents (i.e., oligotherapeutics) for the treatment of cancer, autoimmune disorders, genetic diseases, infectious diseases, neurological diseases, inflammatory diseases, metabolic diseases and others.
    Type: Grant
    Filed: July 27, 2020
    Date of Patent: January 31, 2023
    Assignee: ZATA Pharmaceuticals, Inc
    Inventors: David R. Tabatadze, Ivan B. Yanachkov
  • Patent number: 10738005
    Abstract: Described herein are compositions and compounds having one or more aziridinyl groups, and methods of making the same. The compounds can also have one or more nitrogen atoms that each can be positively charged. The composition and compounds can inactivate one or more nucleic acid molecules (e.g. a DNA and/or a RNA from a pathogen) in a sample. The sample can comprise a blood or blood product (e.g., donated blood). The compositions and compounds can inactivate any nucleic acid present in a blood or blood product, thereby making the blood or blood product safe for use (e.g., in a transfusion).
    Type: Grant
    Filed: December 7, 2018
    Date of Patent: August 11, 2020
    Assignee: ZATA Pharmaceuticals, Inc.
    Inventor: David R. Tabatadze
  • Patent number: 10723755
    Abstract: Compositions and compounds of nucleoside phosphoramidites and modified oligonucleotides, each comprising one or more charge-neutralizing moieties according to the formula V wherein represents the point of attachment to the nucleoside phosphoramidite or the oligonucleotide, optionally through a spacer group. The nucleoside phosphoramidites permit facile attachment of the neutralizing moieties on the backbones of the modified oligonucleotides. The modified oligonucleotides can be used as therapeutic agents (i.e., oligotherapeutics) for the treatment of cancer, autoimmune disorders, genetic diseases, infectious diseases, neurological diseases, inflammatory diseases, metabolic diseases and others.
    Type: Grant
    Filed: November 18, 2015
    Date of Patent: July 28, 2020
    Assignee: ZATA PHARMACEUTICALS, INC.
    Inventors: David R. Tabatadze, Ivan Yanachkov
  • Patent number: 10173976
    Abstract: Described herein are compositions and compounds having one or more aziridinyl groups, and methods of making the same. The compounds can also have one or more nitrogen atoms that each can be positively charged. The composition and compounds can inactivate one or more nucleic acid molecules (e.g. a DNA and/or a RNA from a pathogen) in a sample. The sample can comprise a blood or blood product (e.g., donated blood). The compositions and compounds can inactivate any nucleic acid present in a blood or blood product, thereby making the blood or blood product safe for use (e.g., in a transfusion).
    Type: Grant
    Filed: November 13, 2014
    Date of Patent: January 8, 2019
    Assignee: ZATA PHARMACEUTICALS, INC.
    Inventor: David R. Tabatadze